Pfizer Inc. (NYSE: PFE) announced the completion of its acquisition of Biohaven Pharmaceutical Holding Company Ltd., the maker of NURTEC® ODT (rimegepant), an innovative migraine therapy approved for both acute treatment and prevention of episodic migraine in adults.
Pfizer completes acquisition of Biohaven Pharmaceuticals
October 6, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022